In early December, the Food and Drug Administration approved a gene-editing treatment for sickle cell disease, the first for any illness. One patient helped pave the way.
Advisers to the Food and Drug Administration meeting Tuesday paved the way for the first treatment of human disease using the gene-editing technique CRISPR. The agency has a December deadline.
Scientists have used a gene-editing technique to make mosquitos allies in the fight against malaria. Environmentalists are troubled by the idea of genetically modifying wild animals.
He Jiankui, who shocked the world in 2018 by announcing the creation of the first gene-edited babies, tells NPR he's now working on a cure for Duchenne muscular dystrophy.
A Mississippi woman's life has been transformed by a treatment for sickle cell disease with the gene-editing technique CRISPR. All her symptoms from a disease once thought incurable have disappeared.
The Third International Summit on Genome Editing concluded Monday with ethicists warning scientists to slow down efforts to use gene-editing to enhance the health of embryos.
The last time this summit convened in 2018, the world was shocked to hear a scientist had created the first gene-edited babies. He was condemned, but gene-editing has continued, with some success.
Using CRISPR to modify certain immune cells could make cancer-fighting immunotherapy more potent for a broader set of patients. Two people who went through the treatment share their stories.
In a first, doctors injected the gene-editing tool CRISPR directly into cells in patients' eyes. The experiment helped these vision-impaired patients see shapes and colors again.
Scientists successfully treated a rare disease with the experimental gene-editing technique. It could open the door to new ways of treating more common disorders in the future.
The unprecedented study involves using the gene-editing technique CRISPR to edit a gene while it's still inside a patient's body. In exclusive interviews, NPR talks with two of the first participants.
The Code Breaker profiles Jennifer Doudna, a Nobel Prize-winning biochemist key to the development of CRISPR, and examines the technology's exciting possibilities and need for oversight.
As the first patient to receive an experimental treatment that relied on the gene-editing technique CRISPR continues to do well 17 months later, more patients seem to be benefiting, too.
